Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 2,271 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the sale, the chief executive officer now owns 283,502 shares of the company’s stock, valued at $84,483,596. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
TMO stock traded up $2.98 during midday trading on Friday, hitting $283.64. 1,226,995 shares of the company’s stock were exchanged, compared to its average volume of 1,647,717. Thermo Fisher Scientific Inc. has a 1-year low of $208.34 and a 1-year high of $305.45. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The business has a 50-day simple moving average of $287.19 and a two-hundred day simple moving average of $280.84. The stock has a market capitalization of $110.74 billion, a PE ratio of 25.51, a P/E/G ratio of 1.81 and a beta of 1.13.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.01 by $0.03. The firm had revenue of $6.32 billion during the quarter, compared to analyst estimates of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. Thermo Fisher Scientific’s revenue was up 3.9% compared to the same quarter last year. During the same period last year, the business posted $2.75 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 12.25 EPS for the current fiscal year.
A number of brokerages have recently weighed in on TMO. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday, July 15th. Credit Suisse Group reiterated a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. ValuEngine downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Needham & Company LLC raised their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $305.27.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: What moving averages are used to define a golden cross?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.